How Long Does It Take for Chanca Piedra to Work on Kidney Stones?

Most clinical studies on chanca piedra and kidney stones use a 12-week protocol, and that three-month window is the shortest timeframe in which researchers have documented measurable reductions in stone number and size. There is no evidence that chanca piedra works in days or even a couple of weeks. The honest picture is more complicated than a single timeline, though, because stone size, the form you take, and whether chanca piedra does anything meaningful at all remain subjects of genuine scientific debate.

What the Clinical Studies Found Over 12 Weeks

The most frequently cited clinical trial on chanca piedra and kidney stones enrolled 56 patients with stones smaller than 10 mm. Participants drank a Phyllanthus niruri infusion (essentially a tea) daily for 12 weeks. Ultrasound assessments showed that the average number of stones per patient dropped from about 3.2 at baseline to about 2.0 after the treatment period. That reduction was statistically meaningful.¹ The study also tracked what happened during a 12-week washout period after participants stopped drinking the infusion, which gives a sense of whether benefits persisted or reversed. The reduction in stone count held to a degree, though this study was not designed to establish chanca piedra as a standalone treatment.

A separate single-arm trial took a different approach: 48 participants swallowed capsules containing 225 mg of dried Phyllanthus niruri leaf extract (combined with magnesium stearate and a small amount of vitamin B6) daily for three months. CT scans taken before and after the intervention showed that stones smaller than 3 mm located in the upper and mid portions of the kidney were expelled entirely. Stones in the 3 to 4 mm range shrank but did not fully pass. Stones larger than that were essentially unaffected.² The researchers concluded that a longer treatment period might be needed for larger stones, though no follow-up trial has confirmed that hypothesis.

Why Stone Size Changes the Timeline

If there is one consistent finding across the available research, it is that chanca piedra appears to do more for small stones than for large ones. In the capsule trial, stones under 3 mm were the ones that cleared. Stones in the 3 to 4 mm range shrank modestly. Anything bigger showed no meaningful change over three months.² This pattern makes intuitive sense: a supplement that modestly shifts urinary chemistry and relaxes smooth muscle is going to have a harder time with a 12 mm stone than with a tiny crystal cluster.

For people with very small stones or stone fragments left after a procedure like lithotripsy, three months appears to be a reasonable minimum window to look for results. For larger stones, no existing evidence supports a specific timeline at all, and the honest answer is that chanca piedra may simply not work for them. The researchers themselves recommended longer treatment durations for bigger stones, but that recommendation was speculative, not evidence-based.

How Chanca Piedra Is Thought to Help

The name “chanca piedra” translates to “stone breaker” in Spanish, which sets expectations higher than the science supports. The herb does not shatter stones the way lithotripsy does. Instead, the proposed mechanisms are subtler and work over weeks rather than hours.

The first mechanism involves changes to urinary chemistry. In the 56-patient trial, participants with high urinary oxalate saw their levels drop roughly in half over 12 weeks. Patients with elevated uric acid in their urine also experienced a decrease. At the same time, urinary magnesium and potassium both increased.¹ Both magnesium and potassium are considered inhibitors of stone formation, so shifting the ratio of stone promoters to stone inhibitors in urine could slow crystal growth and make it easier for the body to dissolve or pass smaller fragments over time.

The second mechanism involves interference with the crystallization process itself. Reviews of the laboratory and clinical literature have found that Phyllanthus niruri disrupts the way calcium oxalate crystals form and aggregate, potentially preventing tiny crystals from clumping into larger, harder-to-pass stones.² This matters more for prevention than for treating stones that already exist, but it could explain why stone counts dropped in the clinical trial even among patients whose individual stones did not dramatically shrink.

The third proposed mechanism is smooth muscle relaxation. One of the alkaloids in Phyllanthus niruri, nor-securinine, has antispasmodic properties. Research suggests the plant promotes ureteral relaxation, which could ease the passage of small stones and fragments through the urinary tract.³ The same compound appears to reduce the urinary excretion of calcium and other substances that promote crystal formation. If this mechanism works in living humans the way it appears to in laboratory settings, it would partly explain why very small stones were the ones that passed in the capsule trial. A relaxed ureter and smaller stone is a more favorable combination than a relaxed ureter and a large stone.

The Evidence Is Thinner Than Supplement Marketing Suggests

It is worth being direct about the quality of the research here. A systematic review and meta-analysis looking specifically at Phyllanthus niruri found limited clinical evidence supporting its ability to reduce stone size.² The two trials described above, while promising in the direction of their results, each had small sample sizes and no placebo control group. The 56-patient study was observational with a washout period, and the 48-participant study was a single-arm design, meaning everyone received the treatment and there was no untreated comparison group. Without that comparison, you cannot rule out that the improvements would have happened anyway, since small stones sometimes pass on their own with adequate hydration and time.

Another review called explicitly for randomized controlled trials to pin down chanca piedra’s therapeutic properties, noting that while the preventive effect on stone formation had some support, the evidence for treating existing stones was less convincing.² This distinction between prevention and treatment matters. The urinary chemistry changes are real and well-documented: lower oxalate, lower uric acid, higher magnesium. Those shifts should, in theory, reduce the risk of new stones forming. Whether they meaningfully dissolve or shrink stones that already exist is the part of the claim where the evidence gets thin.

So when someone asks how long chanca piedra takes to work, part of the honest answer is that “work” needs defining. If “work” means changing your urine composition in ways that discourage stone formation, the answer might be a few weeks to a couple of months. If “work” means passing or dissolving an existing stone, the answer is three months at minimum for very small stones, and for larger stones, potentially not at all based on current evidence.

The Oxalate Problem

Here is something that rarely appears in the marketing material for chanca piedra supplements: the herb itself contains oxalate. An analysis of purportedly stone-fighting supplements found that chanca piedra contained about 8.2 mg of oxalate per dose.⁴ For context, calcium oxalate stones are the most common type of kidney stone, and dietary oxalate contributes to their formation. Taking a supplement to reduce stone risk that itself adds oxalate to your system is, at best, counterproductive for some people.

Whether 8.2 mg per dose is clinically meaningful depends on your overall daily oxalate intake and your individual stone chemistry. A person eating a low-oxalate diet might absorb a higher proportion of that supplemental oxalate. Someone whose stones are composed of uric acid rather than calcium oxalate faces a different risk profile entirely. The point is that the assumption behind many supplement marketing campaigns, that chanca piedra is uniformly helpful for all kidney stone patients, does not hold up under scrutiny. If you have calcium oxalate stones and are taking chanca piedra, you could be working against yourself depending on the dose and your overall oxalate load.

Tea Versus Capsules

The two main clinical trials used different forms. The 56-patient study used a Phyllanthus niruri infusion, essentially a brewed tea, which was consumed daily. The 48-participant study used standardized capsules containing 225 mg of dried leaf extract combined with magnesium stearate and vitamin B6. Both used a three-month treatment period, and both reported some degree of stone reduction in small stones, so neither form appears dramatically superior based on the existing evidence.

In practice, the tea form is what has been used traditionally in South America and parts of Asia for centuries. You steep the dried herb in hot water, and drink it once or twice daily. Capsules offer more consistent dosing because the amount of active compound per serving is standardized, whereas the strength of a brewed tea varies depending on steeping time, water temperature, and the quality of the dried herb. For someone trying to replicate what was used in the clinical trials, the capsule study at least provides a specific dose: 225 mg of dried extract per day. The tea study does not specify exact grams of herb per cup, which makes it harder to know whether you are matching the research protocol.

Supplement quality is another practical concern. Chanca piedra products are sold as dietary supplements, which in many countries means they do not undergo the same pre-market testing as pharmaceutical drugs. The concentration of active compounds can vary widely between brands, and some products contain fillers or contaminants. Without standardization, two people taking “chanca piedra capsules” might be getting very different amounts of the relevant alkaloids and other bioactive compounds.

When Chanca Piedra Should Not Replace Medical Treatment

Kidney stones that cause acute obstruction, severe pain, infection, or impaired kidney function need medical intervention. Chanca piedra, even if all of its proposed mechanisms work as hypothesized, operates on a timescale of months. A stone blocking the ureter and causing hydronephrosis cannot wait three months for a supplement to maybe help. Procedures like ureteroscopy, shock wave lithotripsy, and percutaneous nephrolithotomy exist because some stones require prompt removal.

Even for smaller stones being managed conservatively with hydration and time, chanca piedra should be discussed with a doctor rather than self-prescribed. The urinary chemistry changes documented in the trials, such as lower oxalate and uric acid, could interact with other medications or conditions. People taking anticoagulants, diabetes medications, or blood pressure drugs should be cautious, since Phyllanthus niruri has been studied for effects on blood sugar and blood pressure in other contexts, and interactions are plausible even if not fully mapped out.

For stone formers interested in using chanca piedra as a preventive measure between episodes, the evidence for urinary chemistry changes is more encouraging than the evidence for treating existing stones. Reducing oxalate excretion in someone with hyperoxaluria, or reducing uric acid in someone with hyperuricosuria, targets known metabolic risk factors for recurrence.¹ That said, established dietary and pharmacological approaches to these same problems, like potassium citrate supplementation and low-oxalate diets, have a much stronger evidence base.

What Happens After You Stop Taking It

The 56-patient infusion study included a 12-week washout period after participants stopped drinking the tea. This design choice is useful because it tells you something about whether the effects of chanca piedra persist or vanish once you stop.¹ The study found that stone counts remained lower than baseline after the washout, suggesting some lasting benefit. But the urinary chemistry changes, such as the shifts in oxalate and uric acid excretion, are likely tied to ongoing intake. Stop taking the herb, and your urine composition will gradually return to its pre-treatment pattern, since you have removed the agent that was altering it.

This raises a practical question that none of the existing trials answer well: if chanca piedra works for prevention, do you need to take it indefinitely? And if so, does the long-term oxalate exposure from the supplement itself become a problem? Nobody knows. The longest clinical trial lasted 12 weeks of active treatment. There is no published data on outcomes after six months, a year, or longer of continuous use. For a supplement marketed as a natural long-term solution to kidney stone recurrence, that gap in the evidence is meaningful. People who start taking chanca piedra and plan to continue indefinitely are making a decision in a data vacuum, which is not inherently wrong but is worth being aware of.